Your browser doesn't support javascript.
Passive transfer of Ad26.COV2.S-elicited IgG from humans attenuates SARS-CoV-2 disease in hamsters.
Tostanoski, Lisa H; Chandrashekar, Abishek; Patel, Shivani; Yu, Jingyou; Jacob-Dolan, Catherine; Chang, Aiquan; Powers, Olivia C; Sellers, Daniel; Gardner, Sarah; Barrett, Julia; Sanborn, Owen; Stephenson, Kathryn E; Ansel, Jessica L; Jaegle, Kate; Seaman, Michael S; Porto, Maciel; Lok, Megan; Spence, Brittany; Cayer, Kathleen; Nase, Danielle; Holman, Shaikim; Bradette, Heath; Kar, Swagata; Andersen, Hanne; Lewis, Mark G; Cox, Freek; Tolboom, Jeroen T B M; de Groot, Anne Marit; Heerwegh, Dirk; Le Gars, Mathieu; Sadoff, Jerald; Wegmann, Frank; Zahn, Roland C; Schuitemaker, Hanneke; Barouch, Dan H.
  • Tostanoski LH; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Chandrashekar A; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Patel S; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Yu J; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Jacob-Dolan C; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Chang A; Harvard Medical School, Boston, MA, USA.
  • Powers OC; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Sellers D; Harvard Medical School, Boston, MA, USA.
  • Gardner S; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Barrett J; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Sanborn O; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Stephenson KE; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Ansel JL; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Jaegle K; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Seaman MS; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Porto M; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Lok M; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Spence B; BIOQUAL, Inc., Rockville, MD, USA.
  • Cayer K; BIOQUAL, Inc., Rockville, MD, USA.
  • Nase D; BIOQUAL, Inc., Rockville, MD, USA.
  • Holman S; BIOQUAL, Inc., Rockville, MD, USA.
  • Bradette H; BIOQUAL, Inc., Rockville, MD, USA.
  • Kar S; BIOQUAL, Inc., Rockville, MD, USA.
  • Andersen H; BIOQUAL, Inc., Rockville, MD, USA.
  • Lewis MG; BIOQUAL, Inc., Rockville, MD, USA.
  • Cox F; BIOQUAL, Inc., Rockville, MD, USA.
  • Tolboom JTBM; BIOQUAL, Inc., Rockville, MD, USA.
  • de Groot AM; Janssen Vaccines & Prevention, Leiden, The Netherlands.
  • Heerwegh D; Janssen Vaccines & Prevention, Leiden, The Netherlands.
  • Le Gars M; Janssen Vaccines & Prevention, Leiden, The Netherlands.
  • Sadoff J; Janssen Research & Development, Beerse, Belgium.
  • Wegmann F; Janssen Vaccines & Prevention, Leiden, The Netherlands.
  • Zahn RC; Janssen Vaccines & Prevention, Leiden, The Netherlands.
  • Schuitemaker H; Janssen Vaccines & Prevention, Leiden, The Netherlands.
  • Barouch DH; Janssen Vaccines & Prevention, Leiden, The Netherlands.
NPJ Vaccines ; 7(1): 2, 2022 Jan 10.
Article in English | MEDLINE | ID: covidwho-1616986
ABSTRACT
SARS-CoV-2 Spike-specific binding and neutralizing antibodies, elicited either by natural infection or vaccination, have emerged as potential correlates of protection. An important question, however, is whether vaccine-elicited antibodies in humans provide direct, functional protection from SARS-CoV-2 infection and disease. In this study, we explored directly the protective efficacy of human antibodies elicited by Ad26.COV2.S vaccination by adoptive transfer studies. IgG from plasma of Ad26.COV2.S vaccinated individuals was purified and transferred into naïve golden Syrian hamster recipients, followed by intra-nasal challenge of the hamsters with SARS-CoV-2. IgG purified from Ad26.COV2.S-vaccinated individuals provided dose-dependent protection in the recipient hamsters from weight loss following challenge. In contrast, IgG purified from placebo recipients provided no protection in this adoptive transfer model. Attenuation of weight loss correlated with binding and neutralizing antibody titers of the passively transferred IgG. This study suggests that Ad26.COV2.S-elicited antibodies in humans are mechanistically involved in protection against SARS-CoV-2.
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Randomized controlled trials Topics: Vaccines Language: English Journal: NPJ Vaccines Year: 2022 Document Type: Article Affiliation country: S41541-021-00427-z

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Randomized controlled trials Topics: Vaccines Language: English Journal: NPJ Vaccines Year: 2022 Document Type: Article Affiliation country: S41541-021-00427-z